跳到正文
原文
Medical Xpress·· 2026-10-13AI 评分49

真实世界研究:glecaprevir-pibrentasvir 用于14例妊娠期丙肝患者,完成治疗的10例均获病毒学应答

New research shows promise for treating hepatitis C in pregnancy

AI 导读

WashU Medicine 团队在 Clinical Infectious Diseases 发表真实世界研究,14例妊娠14至32周的丙肝患者接受口服 glecaprevir-pibrentasvir 治疗,其中10例完成疗程,均在分娩时或更早达到病毒学应答,研究者未报告母婴安全性问题。

正文
New research shows promise for treating hepatitis C in pregnancy
The study examined the use of an HCV treatment in 14 pregnant patients. Patients received treatment between 14 and 32 weeks of gestation. Of the 14 patients, 10 completed the treatment. All 10 patients who completed treatment achieved virologic response by the time of delivery or earlier. Investigators reported no maternal or neonatal safety concerns. Their study shows early evidence that HCV treatment during pregnancy may be feasible when carefully managed through shared decision-making. Credit: Washington University in St. Louis

Researchers and clinicians at WashU Medicine are helping reshape how hepatitis C virus (HCV) is treated during pregnancy, with a new study showing that a commonly used antiviral regimen can be used safely and effectively in pregnant patients in real-world care.

The study, led by Laura Marks, M.D., Ph.D., and Madeline McCrary, M.D., examined the use of glecaprevir-pibrentasvir, an oral HCV treatment, in 14 pregnant patients treated between 14 and 32 weeks of gestation. Of the 14 patients prescribed the medication, 10 completed the treatment. All 10 of those patients achieved virologic response by the time of delivery or earlier.

Investigators reported no maternal or neonatal safety concerns, adding to growing evidence that HCV treatment during pregnancy may be feasible when carefully managed through shared decision-making. Their findings were published Aug. 11 in Clinical Infectious Diseases.

The findings are especially meaningful because, until now, there had been no clinical trial data and no real-world experience published for glecaprevir-pibrentasvir treatment in pregnancy. The study helps fill an important gap for clinicians caring for pregnant patients with HCV, a population that has historically had limited treatment options during pregnancy despite the potential benefits of reducing maternal infection and preventing transmission to infants.

The work is part of a broader effort led by WashU Medicine teams in infectious diseases and maternal health to improve care for patients across the region. "We really reach people in St. Louis, all over Missouri, and in southern Illinois," said co-author Madeline McCrary, MD, an assistant professor of medicine. The project brings together medication research, implementation science, and health economics to build a new model of care for HCV in pregnancy.

Researchers say the collaboration has already produced multiple papers spanning treatment outcomes, implementation of the new care model, and its cost-effectiveness. Together, they point to a growing local effort with potential implications far beyond the region—one that could help expand access to HCV treatment for pregnant patients while improving outcomes for families.

Publication details

L Madeline McCrary et al., Real-World Experience of Hepatitis C Treatment With Glecaprevir-Pibrentasvir During Pregnancy, Clinical Infectious Diseases (2026). DOI: 10.1093/cid/ciag422

Journal information: Clinical Infectious Diseases

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: New research shows promise for treating hepatitis C in pregnancy (2026, October 12) retrieved 12 October 2026 from https://medicalxpress.com/news/2026-10-hepatitis-pregnancy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com